|
|
|||||
|
|
|||||
|
|
|||||
|
Diversion of Initial Blood Flow to Prevent Contamination of Blood Cultures (US patent 6,913,580)
Clinical trials on diversion of initial blood flow are underway and in the next year complete data from tens of thousands of blood cultures will determine exactly how far Clean Collect can reduce blood culture contamination rates. The technical objective of Clean Collect is to reduce contamination rates to less than 1%. This benefits patients by preventing unnecessary treatment and provides physicians with a more reliable diagnostic test for septicemia. The cost reduction for hospitals ranges from $3.2 million - $18.8 million each year. Learn more about the Clean CollectTM Blood Collection Kit, or the Significance of reducing blood culture contamination.
|
|||||
|
visit www.cleancollect.com for more information
Home | Entrepreneurs | Research | Clinical Laboratories | Careers | About Us Contact Us | Latest News | Investor Relations
|
|||||
|
Stone Medical Corporation © 2007 All Rights Reserved. |
|||||